Whether you are pursuing patents on your new technology, thinking about bringing patent infringement litigation or defending patent infringement claims in court, knowing the important developments in patent law will help you formulate strategy and can spark a change in your procedures or decision-making process. Laura Smalley, partner with our Intellectual Property Law group, summarizes key judicial holdings in patent law from the Federal Circuit during 2020.
Skinny Label Does Not Prevent Claim of Induced Infringement - Rehearing en banc granted February 9, 2021 -
Carvedilol, marketed by GlaxoSmithKline with the brand name Coreg®, was initially approved by the FDA for the treatment of hypertension. The FDA eventually approved three indications for carvedilol: hypertension, left ventricular dysfunction following a myocardial infarction, and congestive heart failure. After the patent on carvedilol expired on March 5, 2007, the only use covered by a patent was for the treatment of congestive heart failure.
Please see full publication below for more information.
